Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 4/20 | 0.51 |
| ▸ | TNKS2 | Q9H2K2 | 4/20 | 0.51 |
| ▸ | PGR | P06401 | 9/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31472145 | 1.00 | TNKS (0.51) | TNKSTNKS2PGRBACE1PDE7A | |
| SCHEMBL24481758 | 0.96 | TNKS (0.51) | TNKSTNKS2PGRBACE1PDE7A | |
| SCHEMBL4719403 | 0.95 | TNKS (0.50) | TNKSTNKS2PGRBACE1PDE7A | |
| SCHEMBL31472193 | 0.93 | TNKS (0.50) | TNKSTNKS2PGRBACE1PDE7A | |
| SCHEMBL3866633 | 0.93 | TNKS (0.50) | TNKSTNKS2PGRBACE1PDE7A | |
| SCHEMBL20954874 | 0.86 | BACE1 (0.51) | TNKSTNKS2PGRBACE1OPRM1 | |
| SCHEMBL15650376 | 0.85 | TNKS (0.46) | TNKSTNKS2PGRBACE1HDAC4 | |
| SCHEMBL16687077 | 0.80 | PGR (0.50) | TNKSTNKS2PGRBACE1PDE7A | |
| SCHEMBL31591814 | 0.79 | TNKS (0.51) | TNKSTNKS2PGRBACE1PDE7A | |
| SCHEMBL29076873 | 0.79 | PGR (0.46) | TNKSTNKS2PGRBACE1PDE7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2602254-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-06-14 | — | — | EP | disclosed |
| US-9090586-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-07-28 | — | — | US | disclosed |
| US-20130150344-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-13 | — | — | US | disclosed |
| EP-2602254-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2013-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150344-A1 | HETEROCYCLIC COMPOUND | PDE5A, PDE3A, PDE3B | TNKS 3380/4885TNKS2 4045/4885PGR 3043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.